A5035148126- Cytokine Signaling Pathways and Interactions
- Cancer Mechanisms and Therapy
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Biochemical and Molecular Research
- Toxin Mechanisms and Immunotoxins
- Cancer-related Molecular Pathways
The First Affiliated Hospital, Sun Yat-sen University
2023
Sun Yat-sen University
2023
Abstract The PI3K–AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. Although inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry–based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT undergoes...
<p>Including supplementary figure S1-9</p>
<p>Including supplementary figure S1-9</p>
<div>Abstract<p>The PI3K-AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. While inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry-based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT...
<div>Abstract<p>The PI3K–AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. Although inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry–based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds...
<div>Abstract<p>The PI3K-AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. While inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry-based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT...
<p>Including supplementary figure S1-9</p>
<p>Including supplementary figure S1-9</p>